{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:57:22Z","timestamp":1776128242498,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.wneu.2017.08.122","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T14:03:31Z","timestamp":1504274611000},"page":"1053.e1-1053.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex"],"prefix":"10.1016","volume":"107","author":[{"given":"Tao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Raynald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunde","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2017.08.122_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.wneu.2017.08.122_bib2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000254570","article-title":"Tuberous sclerosis: epidemiology, genetics and progress towards treatment","volume":"33","author":"Morrison","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.wneu.2017.08.122_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","article-title":"Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012","volume":"49","author":"Roth","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.wneu.2017.08.122_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.wneu.2017.08.122_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2017.08.122_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pediatrneurol.2012.02.015","article-title":"Emerging treatments in the management of tuberous sclerosis complex","volume":"46","author":"Kohrman","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.wneu.2017.08.122_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00381-010-1159-1","article-title":"The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis","volume":"27","author":"Jiang","year":"2011","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.wneu.2017.08.122_bib8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","article-title":"Causes of death in patients with tuberous sclerosis","volume":"66","author":"Shepherd","year":"1991","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.wneu.2017.08.122_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3171\/2013.9.PEDS13193","article-title":"A\u00a0management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"13","author":"Harter","year":"2014","journal-title":"J\u00a0Neurosurg Pediatr"},{"key":"10.1016\/j.wneu.2017.08.122_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00381-011-1406-0","article-title":"The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective","volume":"27","author":"Moavero","year":"2011","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.wneu.2017.08.122_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1227\/01.NEU.0000249216.19591.5D","article-title":"Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?","volume":"60","author":"de Ribaupierre","year":"2007","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2017.08.122_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pediatrneurol.2013.12.004","article-title":"Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients","volume":"50","author":"Kotulska","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.wneu.2017.08.122_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00381-002-0700-2","article-title":"Subependymal giant cell astrocytoma in children with tuberous sclerosis","volume":"19","author":"Cuccia","year":"2003","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.wneu.2017.08.122_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/03007995.2012.658907","article-title":"Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis","volume":"28","author":"Sun","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.wneu.2017.08.122_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejpn.2012.12.008","article-title":"Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"17","author":"J\u00f3\u017awiak","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.wneu.2017.08.122_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/pbc.25368","article-title":"Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis","volume":"62","author":"Trelinska","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.wneu.2017.08.122_bib17","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/0883073813501870","article-title":"Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention","volume":"29","author":"Wheless","year":"2014","journal-title":"J\u00a0Child Neurol"},{"issue":"10 Suppl","key":"10.1016\/j.wneu.2017.08.122_bib18","doi-asserted-by":"crossref","first-page":"S42.007","DOI":"10.1212\/WNL.82.10_supplement.S42.007","article-title":"Everolimus long-term efficacy and safety for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) (S42.007)","volume":"82","author":"Franz","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2017.08.122_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/157015912804499537","article-title":"mTOR inhibitors in tuberous sclerosis complex","volume":"10","author":"Curatolo","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.wneu.2017.08.122_bib20","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-04-3640","article-title":"Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase\/protein kinase B inhibitors","volume":"65","author":"Takeuchi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2017.08.122_bib21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1471-4892(03)00071-7","article-title":"Targeting mTOR signaling for cancer therapy","volume":"3","author":"Huang","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.wneu.2017.08.122_bib22","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1038\/sj.onc.1205923","article-title":"Role of the phosphatidylinositol 3-kinase\/Akt and mTOR\/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma","volume":"21","author":"Pene","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.wneu.2017.08.122_bib23","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2004-09-3540","article-title":"Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF","volume":"105","author":"Guba","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2017.08.122_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11626-015-9944-5","article-title":"Anticancer effect of rapamycin on MCF-7 via down-regulation of VEGF expression","volume":"52","author":"Fujii","year":"2016","journal-title":"In\u00a0Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.wneu.2017.08.122_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exer.2014.11.005","article-title":"Effects of mTOR inhibition on normal retinal vascular development in the mouse","volume":"129","author":"Yagasaki","year":"2014","journal-title":"Exp Eye Res"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875017314237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875017314237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:09:59Z","timestamp":1761811799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875017314237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":25,"alternative-id":["S1878875017314237"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2017.08.122","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2017.08.122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}